Nymox NX-1207 BPH and Prostate Cancer Symposium at American Urological Association Annual Meeting May 5 in San Diego
April 11 2013 - 9:50AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to
announce an important upcoming symposium and panel discussion on
its first-in-class investigational drug NX-1207, currently in late
stage Phase 3 for benign prostatic hyperplasia (BPH) and Phase 2
for Prostate Cancer. The symposium will be held during the 2013
Annual Meeting of the American Urological Association in San Diego
CA 3:00 p.m. May 5 in the San Diego Convention Center.
The symposium, "Clinical studies of NX-1207: Phase 3 Injectable
for BPH (Phase 2 for Prostate Cancer)," will be chaired by Ronald
Tutrone Jr, MD, FACS of Towson, MD, who has participated in four of
the prospective NX-1207 clinical trials as well as follow-up
studies. Dr. Tutrone will present the latest information about
NX-1207 and the NX-1207 clinical trials to date, including the two
Phase 3 BPH clinical trials, and the Phase 2 prostate cancer trials
currently in progress.
There will be seven symposium panelists who are distinguished
Board-certified urologists with extensive experience as clinical
investigators in FDA-regulated clinical trials, including the
NX-1207 clinical trials.
Further information concerning the NX-1207 Symposium will follow
separately in the near future.
NX-1207 is a novel patented drug developed by Nymox which is
currently in Phase 3 trials for BPH and Phase 2 for localized
prostate cancer. The drug has successfully completed a series of
blinded controlled multi-center U.S. clinical trials where a single
dose of NX-1207 has been found to produce on average symptomatic
improvements about double that reported for currently approved BPH
drugs without causing the sexual or cardiovascular side effects
associated with those drugs. Follow-up studies have shown evidence
of long lasting benefit with a significant proportion of men who
received a single dose reporting maintained improvement in BPH
symptoms without other treatments for up to 7½ years.
NX-1207 is in Phase 3 the last stage before filing with the FDA
for approval. NX-1207 is injected by a urologist in an office
setting and involves little or no pain or discomfort. For more
information about the NX-1207 Phase 3 clinical trials please go to
www.clinicaltrials.gov or contact Nymox at info@nymox.com.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Brian Doyle
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024